Peter Ordentlich

Peter Ordentlich has a Ph.D. in Immunology from the University of Pennsylvania and has a strong background in scientific research. Peter has held various scientific positions at Salk Institute, X-Ceptor Therapeutics, and currently serves as the Chief Scientific Officer and Vice President of Translational Medicine at Syndax Pharmaceuticals.